IBD: Crohn's vs. Ulcerative Colitis — IBD (Crohn vs ulcerative colitis) pathophysiology overview - Pathophysiology

SECTION 1

Historical Context & Discovery of IBD

The recognition of inflammatory bowel disease (IBD) as a distinct set of chronic inflammatory conditions of the gastrointestinal tract evolved over more than a century. Early physicians described chronic diarrhea and intestinal ulceration in vague clinical terms, often conflating infectious colitis with what we now understand to be immune-mediated inflammation. The eventual separation of Crohn's disease from ulcerative colitis as two pathologically distinct entities represents one of the landmark achievements in gastroenterology, enabling targeted diagnostic approaches and disease-specific therapeutic strategies that continue to evolve today.

1859 • Samuel Wilks Describes Ulcerative Colitis

British physician Samuel Wilks published the first clear clinical and pathological description of a young woman with diffuse colonic inflammation and ulceration, coining the term ulcerative colitis and establishing it as a discrete disease entity separate from infectious dysentery.

1932 • Crohn, Ginzburg & Oppenheimer Define Regional Ileitis

Burrill B. Crohn and colleagues at Mount Sinai Hospital published their seminal paper describing 14 cases of regional ileitis — a granulomatous, transmural inflammation of the terminal ileum that was distinct from tuberculosis and ulcerative colitis.

1960s • Recognition of Crohn's Colitis

Clinicians recognized that Crohn's disease could involve the colon, not just the ileum. This expanded the diagnostic framework and introduced the concept of skip lesions as a distinguishing feature from the continuous mucosal inflammation of ulcerative colitis.

2001 • NOD2/CARD15 Gene Discovery

Identification of mutations in the NOD2/CARD15 gene as the first confirmed susceptibility locus for Crohn's disease provided molecular evidence that innate immune defects contribute to disease pathogenesis, launching the era of IBD genetics.

2012–present • Genome-Wide Association & Microbiome Studies

Large-scale GWAS identified over 240 IBD-associated loci, many shared between Crohn's and UC but with distinct risk alleles. Concurrent microbiome research revealed dysbiosis as a central pathogenic feature, prompting novel therapeutic avenues.

Despite the advances outlined above, a critical question persists: what are the precise immunological and pathological mechanisms that cause the gut's own immune system to mount a destructive, chronic inflammatory response against the intestinal mucosa, and how do these mechanisms diverge in Crohn's disease versus ulcerative colitis? Understanding these pathophysiological distinctions is essential for accurate diagnosis, appropriate medical management, and anticipation of the unique complications each disease can produce.

SECTION 2

Core Principles of IBD Pathophysiology

Both Crohn's disease and ulcerative colitis arise from a complex interplay among four key pathogenic pillars: genetic susceptibility, environmental triggers, intestinal microbiota dysregulation, and a dysregulated mucosal immune response. Although these pillars are shared, the specific defects within each pillar and the downstream inflammatory cascades they activate differ substantially between the two diseases, producing their characteristic histological patterns and clinical presentations. The following foundational concepts provide the framework for understanding how these diseases develop and why they behave differently.

Genetic Susceptibility

Over 240 genetic loci have been associated with IBD. NOD2 mutations specifically predispose to Crohn's, while HLA-DRB1 alleles show stronger associations with ulcerative colitis. Autophagy genes (ATG16L1, IRGM) are more prominent in Crohn's pathogenesis.

Epithelial Barrier Dysfunction

The intestinal epithelium functions as a selective barrier. In IBD, defects in tight junctions, reduced antimicrobial peptide secretion (particularly Paneth cell defensins in Crohn's), and impaired mucus layer integrity increase intestinal permeability, exposing lamina propria immune cells to luminal antigens.

Dysregulated Immune Response

Crohn's disease is driven predominantly by a Th1/Th17 response with elevated IFN-γ, TNF-α, IL-12, IL-17, and IL-23. Ulcerative colitis involves a modified Th2 response with prominent IL-5, IL-13, and IL-4. Both diseases feature excessive TNF-α production.

Microbiome Dysbiosis

IBD patients demonstrate reduced microbial diversity with depletion of beneficial Firmicutes (e.g., Faecalibacterium prausnitzii) and expansion of pathogenic Proteobacteria (e.g., adherent-invasive E. coli in Crohn's). This dysbiosis perpetuates mucosal immune activation.

Environmental Triggers

Smoking is a notable divergent factor — it worsens Crohn's disease but is paradoxically protective in UC. NSAIDs, antibiotics, stress, diet (high fat, low fiber), and prior GI infections all modulate risk through effects on barrier function and microbiome composition.

✦

KEY TAKEAWAY

Think of the healthy gut as a well-managed security checkpoint at an international border: the epithelial barrier is the physical wall, the immune system is the trained security force, and the microbiome is the local population living peacefully on both sides. In IBD, the wall develops cracks (barrier dysfunction), the security force becomes hypervigilant and attacks civilians (dysregulated immunity), and the local population shifts to include hostile agents (dysbiosis). In Crohn's disease, the security force specializes in a scorched-earth Th1/Th17 campaign that burns through the entire wall thickness (transmural inflammation). In ulcerative colitis, the force uses a Th2-oriented surface patrol that systematically strips the wall's coating starting at the border gate and working inward (continuous mucosal inflammation from rectum proximally).

SECTION 3

Visual Comparison: Crohn's vs. Ulcerative Colitis

The following diagram provides a side-by-side cross-sectional view of the bowel wall in Crohn's disease versus ulcerative colitis, illustrating the depth and pattern of inflammation, the presence of granulomas, and the characteristic differences in mucosal architecture. Understanding these histological distinctions is essential for interpreting biopsy findings and correlating pathology with clinical presentation.

Cross-sectional comparison of bowel wall involvement. Left (Crohn's): transmural inflammation extending through all four layers with deep fissuring ulcers, non-caseating granulomas, and skip lesions. Right (UC): inflammation confined to the mucosa and superficial submucosa with continuous superficial ulceration, crypt abscesses, and pseudopolyps.

The diagram above highlights several pathognomonic distinctions. In Crohn's disease, the inflammation is transmural — extending from the mucosa through the submucosa, muscularis propria, and even the serosa. This full-thickness involvement explains Crohn's propensity for strictures (from fibrosis), fistulae (abnormal tracts between organs), and abscesses. The non-caseating granulomas, present in approximately 30% of biopsy specimens, are a hallmark finding when present. In contrast, ulcerative colitis demonstrates inflammation confined to the mucosa and superficial submucosa, with characteristic crypt abscesses (neutrophilic infiltration into the crypts of Lieberkühn) and eventual crypt architectural distortion. Because the muscularis is spared, fistulae and strictures are exceedingly rare in UC, though toxic megacolon represents a feared complication when inflammation is severe enough to impair colonic motility.

SECTION 4

Immunopathogenic Mechanisms in Depth

Crohn's Disease: Th1/Th17-Dominated Pathways

The immunopathogenesis of Crohn's disease centers on a dysregulated innate immune response that activates a predominantly Th1 and Th17 adaptive immune cascade. The process begins at the epithelial barrier, where defects in Paneth cell function — often linked to NOD2 mutations and autophagy gene polymorphisms (ATG16L1, IRGM) — reduce α-defensin secretion and impair intracellular bacterial clearance. This allows commensal and pathogenic bacteria to breach the epithelial barrier and activate antigen-presenting cells (dendritic cells and macrophages) in the lamina propria. These APCs produce IL-12 and IL-23, which drive naïve CD4⁺ T cells toward Th1 and Th17 differentiation, respectively. Th1 cells secrete IFN-γ and TNF-α, activating macrophages and promoting granuloma formation. Th17 cells produce IL-17A, IL-17F, and IL-22, which recruit neutrophils and amplify tissue destruction. The sustained production of TNF-α by macrophages is a critical amplification loop, which is why anti-TNF biologics (infliximab, adalimumab) are effective therapeutic agents.

Ulcerative Colitis: Modified Th2 Pathways

Ulcerative colitis is characterized by a modified Th2 immune response that involves atypical natural killer T (NKT) cells producing substantial quantities of IL-13. This cytokine is directly cytotoxic to epithelial cells, impairs tight junction integrity, and induces goblet cell depletion — contributing to the characteristic mucus layer thinning observed in UC. Additional Th2 cytokines including IL-5 and IL-4 promote eosinophilic infiltration and B cell class switching to IgG1 and IgE. The inflammatory infiltrate in UC is rich in neutrophils that migrate into the crypt lumen to form crypt abscesses, a histological hallmark. Unlike Crohn's, granulomas are absent. The inflammation begins at the rectum and extends proximally in a continuous fashion, reflecting the idea that the rectal mucosa is particularly vulnerable to the cytotoxic effects of IL-13 and the high antigen load from the fecal stream. TNF-α also plays a significant role in UC, though the IL-13/NKT cell axis is more disease-specific.

Immunopathogenic cascade comparison. Crohn's (left): IL-12/IL-23 → Th1/Th17 → IFN-γ, TNF-α, IL-17 → transmural inflammation. UC (right): NKT cell-driven modified Th2 → IL-13 cytotoxicity → mucosal inflammation. Both converge on TNF-α as a shared therapeutic target.

💡

Clinical Correlation

The distinction between Th1/Th17 (Crohn's) and modified Th2 (UC) pathways has direct therapeutic implications. Ustekinumab targets the shared p40 subunit of IL-12 and IL-23 and is particularly effective in Crohn's. Vedolizumab, an α4β7 integrin inhibitor, blocks gut-selective lymphocyte trafficking and is approved for both diseases. Anti-TNF agents (infliximab, adalimumab) work in both because TNF-α is a shared downstream effector.

SECTION 5

Anatomical Distribution & Complications

One of the most clinically consequential differences between Crohn's disease and ulcerative colitis is their anatomical distribution within the gastrointestinal tract. Crohn's disease can affect any segment from mouth to anus, though the terminal ileum and ileocecal region are the most commonly involved sites, present in approximately 40% of cases. Isolated colonic Crohn's occurs in roughly 30% of patients, while isolated small bowel disease accounts for another 30%. The hallmark of Crohn's anatomical involvement is the presence of skip lesions — discrete areas of inflammation separated by segments of grossly normal bowel. This patchy distribution gives the mucosal surface its characteristic cobblestone appearance on endoscopy.

Ulcerative colitis, by contrast, is exclusively a disease of the colon and rectum. It invariably begins at the rectum and extends proximally in a continuous, circumferential pattern without skip lesions. The extent of colonic involvement is classified as proctitis (rectum only), left-sided colitis (up to the splenic flexure), or pancolitis (involving the entire colon). A notable exception is backwash ileitis, a mild terminal ileal inflammation seen in some patients with pancolitis, which should not be confused with true ileal Crohn's disease.

Feature	Crohn's Disease	Ulcerative Colitis
Location	Mouth to anus (terminal ileum most common)	Colon and rectum only
Distribution pattern	Skip lesions (patchy, discontinuous)	Continuous, starts at rectum, extends proximally
Depth of inflammation	Transmural (all layers)	Mucosal and submucosal only
Granulomas	Non-caseating granulomas (~30%)	Absent
Endoscopic appearance	Cobblestoning, linear/serpiginous ulcers, aphthous ulcers	Diffuse erythema, friability, pseudopolyps, loss of haustra (lead pipe)
Characteristic complications	Strictures, fistulae, abscesses, creeping fat	Toxic megacolon, colorectal cancer risk (pancolitis), primary sclerosing cholangitis
Rectal involvement	Often spared	Always involved
Smoking effect	Worsens disease	Protective (onset often follows cessation)
Surgical cure	No (high recurrence after resection)	Yes (total proctocolectomy is curative)
Serology	ASCA positive (60–70%)	p-ANCA positive (60–70%)

Comprehensive comparison of pathological and clinical features of Crohn's disease versus ulcerative colitis

Extraintestinal Manifestations

Both forms of IBD can present with extraintestinal manifestations (EIMs) affecting the joints, skin, eyes, and hepatobiliary system. Peripheral arthritis, erythema nodosum, and episcleritis tend to correlate with intestinal disease activity and improve with treatment of the underlying IBD. In contrast, ankylosing spondylitis, pyoderma gangrenosum, and primary sclerosing cholangitis (PSC) follow an independent course from gut inflammation. PSC has a particularly strong association with ulcerative colitis, occurring in approximately 5% of UC patients and carrying an independent risk of cholangiocarcinoma.

SECTION 6

Clinical Reasoning: Differentiating Crohn's from UC

The following worked example demonstrates how to integrate clinical history, endoscopic findings, histopathology, and serological markers to differentiate Crohn's disease from ulcerative colitis in a clinical scenario.

Case: 24-Year-Old with Chronic Diarrhea and Abdominal Pain

1
Step 1 — Gather Clinical History

A 24-year-old male presents with a 6-month history of intermittent right lower quadrant abdominal pain, non-bloody diarrhea (4–6 episodes per day), a 7-kg unintentional weight loss, and a perianal fistula. He is a current smoker. Family history reveals a maternal uncle with Crohn's disease. On physical exam, there is tenderness in the right lower quadrant and a draining perianal fistula. These features — RLQ pain, non-bloody diarrhea, fistula, smoking, and weight loss — strongly suggest Crohn's disease rather than UC.

Clinical pattern favors Crohn's disease based on location (RLQ → terminal ileum), fistulizing behavior, and risk factors (smoking, family history).
2
Step 2 — Evaluate Endoscopic Findings

Ileocolonoscopy reveals aphthous ulcers and deep linear ulcers in the terminal ileum with a cobblestone pattern. The cecum shows patchy inflammation, but the transverse colon and rectum appear grossly normal. This discontinuous (skip lesion) pattern with rectal sparing is inconsistent with UC, which would show continuous inflammation beginning at the rectum.

Skip lesions, cobblestoning, and rectal sparing are endoscopic hallmarks of Crohn's disease.
3
Step 3 — Review Histopathology

Biopsies from the ileal ulcers demonstrate transmural inflammation with lymphoid aggregates extending into the submucosa and muscularis propria. Two of six specimens contain non-caseating granulomas. There are no crypt abscesses. This histological pattern is diagnostic of Crohn's disease. In UC, one would expect inflammation limited to the mucosa/submucosa, crypt abscesses with neutrophilic infiltration, and goblet cell depletion — but no granulomas.

Transmural inflammation with non-caseating granulomas confirms Crohn's disease.
4
Step 4 — Interpret Serological Markers

Serology reveals ASCA-positive (anti-Saccharomyces cerevisiae antibodies) and p-ANCA-negative. The ASCA+/p-ANCA− pattern has a specificity of approximately 92–97% for Crohn's disease. Had this been UC, we would expect the reverse pattern: p-ANCA+/ASCA−. While serology alone is insufficient for diagnosis, it supports the clinicopathological impression.

ASCA+/p-ANCA− serology pattern supports Crohn's disease (specificity ≈ 95%).
5
Step 5 — Synthesize Diagnosis and Classify

Integrating all data: the clinical history (RLQ pain, non-bloody diarrhea, perianal fistula, smoking, weight loss), endoscopic findings (skip lesions, cobblestoning, rectal sparing), histopathology (transmural inflammation, non-caseating granulomas), and serology (ASCA+/p-ANCA−) all converge on a diagnosis of Crohn's disease with ileocolonic involvement and perianal fistulizing disease. Using the Montreal classification, this would be A2 (age 17–40), L3 (ileocolonic), B3p (penetrating with perianal disease).

Final Diagnosis: Crohn's disease — Montreal A2, L3, B3p

SECTION 7

Diagnostic Approaches: Strengths and Limitations

Differentiating Crohn's disease from ulcerative colitis requires an integrated multimodal approach, as no single test is pathognomonic. Each diagnostic modality has inherent strengths and limitations that clinicians must understand to avoid misdiagnosis. Approximately 5–15% of patients with colonic IBD remain classified as indeterminate colitis (now often termed IBD-unclassified or IBD-U), underscoring the diagnostic challenge when features overlap.

Diagnostic Modality	Strengths	Limitations
Ileocolonoscopy with biopsies	Gold standard for initial evaluation; direct visualization of mucosal pattern; enables tissue sampling for histology; assesses disease extent and severity	Cannot assess transmural disease depth or extraluminal complications (fistulae, abscesses); invasive procedure; biopsies may miss granulomas due to patchy distribution
CT enterography / MR enterography	Excellent for small bowel Crohn's (strictures, fistulae, abscesses); assesses wall thickness and mesenteric changes; MRE avoids radiation exposure	Limited sensitivity for early mucosal disease; cannot obtain tissue for histology; CTE involves ionizing radiation (important in young IBD patients)
Serological markers (ASCA, p-ANCA)	Non-invasive; high specificity when combined (ASCA+/p-ANCA− for Crohn's ≈ 95% specific); useful adjunct in indeterminate colitis	Low sensitivity (50–60%); cannot determine disease activity, extent, or severity; not recommended as standalone diagnostic tests
Fecal calprotectin	Excellent screening tool to distinguish IBD from IBS; correlates with endoscopic disease activity; non-invasive and inexpensive	Does not differentiate between Crohn's and UC; elevated in any GI inflammation (infections, NSAIDs, malignancy); less reliable in small bowel-only Crohn's
Capsule endoscopy	Superior sensitivity for small bowel mucosal lesions; non-invasive visualization of the entire small bowel	Cannot obtain biopsies; risk of capsule retention in stricturing Crohn's; limited role in UC (colon-only disease)

Strengths and limitations of diagnostic modalities for IBD differentiation

✦

KEY TAKEAWAY

Diagnosing and differentiating IBD subtypes is analogous to assembling a jigsaw puzzle: no single piece (test) gives you the complete picture. The clinical history provides the edges, endoscopy reveals the central image, histopathology fills in the fine details, and serology/imaging add the final pieces. When pieces don't fit neatly — as in 5–15% of colonic IBD cases — the puzzle remains incomplete, and we label it IBD-unclassified, knowing that subsequent evaluations may eventually clarify the diagnosis.

SECTION 8

Connections to Advanced Immunology and Therapeutic Targets

The pathophysiological framework of IBD connects directly to advanced concepts in mucosal immunology, precision medicine, and targeted biologic therapy. As our understanding of the molecular underpinnings of Crohn's and UC has deepened, so has the therapeutic armamentarium, with each new drug targeting a specific node in the inflammatory cascade. Understanding these connections prepares the healthcare student for the rapidly evolving landscape of IBD management.

Foundational Concept	Advanced Extension	Therapeutic Implications
Th1/Th17 vs. modified Th2 paradigm	Emerging data show plasticity between T-helper subsets; Th17 cells can transdifferentiate into Th1 cells (ex-Th17); innate lymphoid cells (ILCs) mirror T-helper subsets in mucosal tissue	Anti-IL-23 (risankizumab, guselkumab) targets upstream of both Th17 and ex-Th17 populations; under investigation for both Crohn's and UC
TNF-α as shared effector	TNF-α exists as membrane-bound (mTNF) and soluble (sTNF) forms; mTNF signaling through TNFR2 may have anti-inflammatory roles; selective sTNF inhibition is under study	Anti-TNF agents (infliximab, adalimumab) block both forms; primary non-response (~30%) or secondary loss of response driven by anti-drug antibodies remains a major limitation
Lymphocyte trafficking to gut	MAdCAM-1/α4β7 integrin interaction mediates gut-selective homing; S1P receptors regulate lymphocyte egress from lymph nodes	Vedolizumab (α4β7 inhibitor) — gut-selective; Ozanimod (S1P receptor modulator) — traps lymphocytes in lymph nodes; approved for UC, under study for Crohn's
JAK-STAT signaling in cytokine pathways	Multiple IBD-relevant cytokines (IL-6, IL-12, IL-23, IFN-γ) signal through JAK1, JAK2, JAK3, TYK2; selective JAK inhibition can target specific cytokine networks	Tofacitinib (JAK1/3) — approved for UC; Upadacitinib (JAK1-selective) — approved for both; filgotinib and deucravacitinib (TYK2) — under investigation
Microbiome-immune crosstalk	Short-chain fatty acids (butyrate) from commensal bacteria promote Treg differentiation and epithelial barrier integrity; dysbiosis disrupts this homeostatic circuit	Fecal microbiota transplantation (FMT) shows promise in UC; defined microbial consortia and next-generation probiotics are in clinical trials

From foundational IBD pathophysiology to advanced immunology and emerging therapeutics

As you advance in clinical training, you will encounter the concept of treat-to-target strategies in IBD, where the goal is no longer symptom control alone but endoscopic and histological remission. This approach, borrowed from rheumatology, relies on the pathophysiological understanding developed in this lesson — selecting biologic agents or small molecules that target the specific immunological pathway driving an individual patient's disease. The future of IBD management lies in biomarker-guided precision medicine, where genetic, serological, microbiome, and transcriptomic profiling will enable truly personalized therapy selection.

SECTION 9

Practice Problems

Question 1: CONCEPTUAL

Explain why Crohn's disease is prone to fistula formation while ulcerative colitis is not. In your answer, reference the specific difference in inflammatory depth between the two diseases.

Show answer

Crohn's disease produces transmural inflammation, meaning the inflammatory process extends through all four layers of the bowel wall — mucosa, submucosa, muscularis propria, and serosa. This full-thickness involvement allows deep fissuring ulcers to erode completely through the bowel wall and create abnormal communication tracts (fistulae) to adjacent structures such as other bowel loops (enteroenteric), the bladder (enterovesical), the skin (enterocutaneous), or the vagina (rectovaginal). In contrast, ulcerative colitis confines its inflammation to the mucosa and superficial submucosa, never reaching the muscularis or serosa, which means the deep tissue destruction necessary for fistula formation does not occur. This is why fistulae are considered a hallmark complication of Crohn's disease and are virtually absent in UC.

Question 2: BASIC CALCULATION

A serological panel reveals ASCA-positive and p-ANCA-negative results. Given that this pattern has a sensitivity of approximately 55% and a specificity of approximately 95% for Crohn's disease, calculate the positive predictive value (PPV) in a population where the prevalence of Crohn's among IBD patients is 55%. Use: PPV = (Sensitivity × Prevalence) / [(Sensitivity × Prevalence) + ((1 − Specificity) × (1 − Prevalence))].

Show answer

Applying the formula: PPV = (0.55 × 0.55) / [(0.55 × 0.55) + ((1 − 0.95) × (1 − 0.55))]. The numerator is 0.55 × 0.55 = 0.3025. The denominator is 0.3025 + (0.05 × 0.45) = 0.3025 + 0.0225 = 0.325. Therefore, PPV = 0.3025 / 0.325 ≈ 0.931, or approximately 93.1%. This means that if a patient with confirmed IBD tests ASCA+/p-ANCA−, there is about a 93% probability that they have Crohn's disease rather than UC. However, this high PPV depends on the pre-test probability (prevalence) and does not replace clinical, endoscopic, and histological assessment.

Question 3: INTERMEDIATE

A 30-year-old woman presents with bloody diarrhea, tenesmus, and colonoscopy showing continuous erythematous, friable mucosa from the rectum to the hepatic flexure. Biopsies show crypt abscesses, goblet cell depletion, and lamina propria inflammation without granulomas. She was recently diagnosed with primary sclerosing cholangitis (PSC). Provide the most likely diagnosis, classify the disease extent, and explain the significance of the PSC association.

Show answer

The most likely diagnosis is ulcerative colitis with extensive disease (Montreal classification E3 — left of hepatic flexure but not pancolitis; however, involvement beyond the splenic flexure to the hepatic flexure is typically classified as extensive/E3). The key supporting features include: bloody diarrhea (characteristic of UC rather than Crohn's), continuous mucosal inflammation starting at the rectum (the hallmark pattern of UC), crypt abscesses and goblet cell depletion on histology (typical of UC), and absence of granulomas (which would suggest Crohn's). The PSC association is highly significant because approximately 70–80% of patients with PSC have concomitant UC, and PSC follows an independent course from the bowel inflammation. Importantly, PSC in UC patients confers an additional risk of cholangiocarcinoma and an increased risk of colorectal neoplasia beyond that associated with UC alone, necessitating enhanced colonoscopic surveillance.

Question 4: APPLIED

A patient with established Crohn's disease has failed treatment with mesalamine and corticosteroids. Their gastroenterologist is considering a biologic agent. Based on the immunopathogenic cascade of Crohn's disease, explain the mechanism of action of: (a) infliximab, (b) ustekinumab, and (c) vedolizumab. Discuss which immunological node each agent targets and how this relates to the Th1/Th17 pathway.

Show answer

All three agents target different nodes in the Crohn's immunopathogenic cascade. (a) Infliximab is a chimeric monoclonal antibody against TNF-α, the key downstream effector cytokine produced by activated macrophages and Th1 cells. By neutralizing both soluble and membrane-bound TNF-α, infliximab interrupts the amplification loop that sustains macrophage activation, granuloma maintenance, and tissue destruction. (b) Ustekinumab targets the shared p40 subunit of IL-12 and IL-23. Since IL-12 drives Th1 differentiation (producing IFN-γ and TNF-α) and IL-23 drives Th17 differentiation (producing IL-17 and IL-22), ustekinumab intervenes upstream of the T-helper cell commitment step, effectively suppressing both arms of the adaptive immune response simultaneously. (c) Vedolizumab targets the α4β7 integrin on lymphocytes, which binds MAdCAM-1 on gut endothelium to mediate gut-selective lymphocyte homing. By blocking this interaction, vedolizumab prevents activated Th1 and Th17 cells from trafficking to the intestinal mucosa, thus reducing local inflammatory infiltration without systemic immunosuppression. The choice among agents depends on disease phenotype, severity, patient comorbidities, and the concept of positioning therapy within the treat-to-target paradigm.

Question 5: CRITICAL THINKING

Approximately 5–15% of patients with colonic IBD are classified as IBD-unclassified (IBD-U). Critically analyze why this diagnostic ambiguity exists by discussing: (1) the overlapping features that create confusion, (2) the limitations of current diagnostic tools, and (3) the potential clinical consequences of misclassifying Crohn's as UC or vice versa, particularly regarding surgical management.

Show answer

IBD-unclassified arises because Crohn's disease confined to the colon can closely mimic UC in several ways: both may present with bloody diarrhea, both may show diffuse colonic inflammation on endoscopy, and both may lack the classic distinguishing features in individual cases (e.g., Crohn's colitis may lack granulomas in 70% of biopsies, and rectal sparing/skip lesions may be subtle or absent). The overlapping features include shared cytokine pathways (TNF-α is central to both), shared genetic susceptibility loci (~30% overlap in GWAS), and similar endoscopic findings when Crohn's colitis is diffuse rather than patchy. Current diagnostic tools have inherent limitations: biopsies sample only a fraction of the mucosa, serological markers (ASCA/p-ANCA) have limited sensitivity (~55–65%), and imaging cannot always distinguish between transmural versus deep mucosal inflammation. The clinical consequences of misclassification are most significant regarding surgical decisions. If a patient believed to have UC undergoes a total proctocolectomy with ileal pouch-anal anastomosis (IPAA, or J-pouch), but actually has Crohn's disease, they face a 30–50% risk of pouch complications including fistulae, strictures, and ultimate pouch failure, because Crohn's disease commonly recurs in the neo-terminal ileum and pouch. Conversely, classifying UC as Crohn's may delay the option of curative proctocolectomy and subject the patient to unnecessary small bowel surveillance. This diagnostic challenge underscores the importance of repeated evaluation over time, as disease reclassification occurs in up to 10% of IBD-U patients within the first 5 years.

SUMMARY

IBD Pathophysiology — Summary Review

Summary

Inflammatory bowel disease encompasses two major entities — Crohn's disease and ulcerative colitis — both arising from the interaction of genetic susceptibility, environmental triggers, microbiome dysbiosis, and dysregulated mucosal immunity. Crohn's disease is driven by a Th1/Th17 immune response producing transmural inflammation that can affect any GI segment (mouth to anus) in a discontinuous skip-lesion pattern, with non-caseating granulomas, strictures, and fistulae as hallmark complications. Ulcerative colitis involves a modified Th2 response with IL-13-mediated epithelial cytotoxicity, producing continuous mucosal inflammation confined to the colon and rectum, characterized by crypt abscesses and pseudopolyps.

Diagnosis relies on integrating clinical history, ileocolonoscopy with biopsies, imaging, and serological markers (ASCA for Crohn's, p-ANCA for UC). Key clinical differentiators include the effect of smoking (worsens Crohn's, protective in UC), the potential for surgical cure (proctocolectomy cures UC; Crohn's recurs after resection), and the association of primary sclerosing cholangitis predominantly with UC. Therapeutic advances — from anti-TNF biologics to anti-IL-12/23 agents, integrin inhibitors, and JAK inhibitors — are rooted directly in the immunopathogenic cascades described in this lesson, making a solid understanding of these pathways essential for evidence-based clinical practice.